Key Drivers
- Net-cash balance
- Operating losses
- Heavy cash burn
AIAI Summary
Galapagos has shifted from discovery-led biotech to a balance-sheet driven dealmaker—its ~€3bn liquid war chest makes the stock a directional bet on disciplined mid/late-stage BD execution and timely restructuring (monitor the EUR150–200m restructuring need, EUR100–125m wind‑down draw and Gilead option mechanics). If management delivers conservative asset buys and reaches cash neutrality targets by end‑2026, upside is credible; missed timelines or dilutive capital moves would likely trigger material downside.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Net-cash balance
- •Operating losses
- •Heavy cash burn
Galapagos shows a strong, net-cash balance sheet and very high gross margins but has swung from modest profitability to steep operating losses and heavy cash burn driven by outsized R&D/OPEX, constraining near-term investment appeal.
Price Behavior
Key Price Behavior Insights:
- •Below moving average
- •Buyers defend low
- •RSI shows weakness
Short-term bias softened: last month's average (~$33.12) sits above the $32.01 close with RSI ~37, signaling downside pressure while buyers repeatedly defend the $31.71 low—failure to reclaim last month's average (~$33.1) keeps the bias bearish.
Repeated bounces off $31.71 in
Sentiment & News
Key News Insights:
- •Subscription rights
- •Senior HR hire
- •Repeated filings
Galapagos released FY2025 results and a Q4 update alongside a new 1.75M subscription-rights plan, multiple rapid transparency filings by Bank of America, and a senior HR appointment, signaling capital-structure action and heightened governance/reporting activity.
The rights plan introduces potential dilution and, together with frequent disclosure activity, may keep investor focus on governance and capital-structure implications in the near term
Similar Companies in Healthcare
Other companies in the same sector with AI ratings